albutrepenonacog alfa

Albutrepenonacog alfa is a recombinant fusion protein consisting of human coagulation factor IX genetically fused to recombinant human albumin. It is designed as a long-acting factor IX replacement therapy for the treatment and prevention of bleeding in adults and children with hemophilia B (congenital factor IX deficiency). The albumin fusion extends the half-life of factor IX, allowing for less frequent intravenous dosing (every 7–21 days depending on patient needs). The drug works by replacing missing or defective factor IX, thereby restoring effective hemostasis. Albutrepenonacog alfa was developed by CSL Behring and is marketed under the brand name Idelvion. It was approved by regulatory agencies including the FDA (2016), EMA (2016), and Health Canada (2017)[1][3][4][5][6][7].

Brand names

Idelvion

Other names

recombinant factor IX albumin fusion protein